Previously an advisor to Index Ventures, Prof. Esteban Cvitkovic is a medical oncologist focused on early stage development of single agent and combination regimens. He has been active for over 40 years, the first 25 years as an academic investigator, and then through a CRO specialized in oncology. The author of over 230 scientific articles and 800 abstracts, Esteban has been responsible for defining the clinical utility and enabling the registration of a variety of oncology drugs. Highlights of his career in industry include co-founding OncoEthix, devoted to novel therapeutic leads and focused on the early development of the first bromodomain inhibitor. The company was sold to Merck in 2014.
Esteban heads the Scientific Board of the Foundation Nélia & Amadeo Barletta, a non-profit entity that supports translational research for individual cancer treatment, and serves on scientific boards for several biotechnology companies.
Esteban did his clinical and oncology training in Buenos Aires, Institute Tumori, Milan and Memorial Sloan Kettering, New York , and his Pharmacology at Mario Negri in Milan.